NCT02748694View on ClinicalTrials.gov

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

September 22, 2019

Study Completion Date

September 22, 2019

Conditions
Healthy VolunteersSchizophrenia
Interventions
DRUG

TAK-041

TAK-041 tablets or oral suspension.

DRUG

TAK-041 Placebo

TAK-041 placebo-matching suspension or tablet.

Trial Locations (1)

91206

Parexel Early Phase Clinic Unit- Los Angeles, Glendale

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY